



300 NW 70<sup>th</sup> Avenue, Suite 102 • Plantation, Florida 33317  
(954) 723-0057 Phone • (954) 723-0353 Fax  
email: [info@naceonline.com](mailto:info@naceonline.com)

**Clinical Updates for  
Nurse Practitioners and  
Physician Assistants: 2012/2013**



**October 27, 2012  
Charlotte Marriott City Center  
Charlotte, NC**

**Course Directors  
Deborah Paschal, CRNP  
Gregg Sherman, MD**

**Activity Director  
Michelle Frisch, MPH, CCMEP**

**Program Evaluation  
November 30, 2012**

In October 2012, the National Association for Continuing Education (NACE) sponsored a CE activity, *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Charlotte, NC.

This educational activity was designed to provide nurse practitioners and physician assistants the opportunity to learn about Osteoporosis, Psoriasis, Inflammatory Bowel Disease, Diabetes, and Atrial Fibrillation.

In planning this CE activity, NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Sixty seven healthcare practitioners registered to attend *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Charlotte, NC. Forty one healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Forty one completed forms were received. The data collected is displayed in this report.

#### CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.


Physician assistants may receive a maximum of 6 hours of Category 1 credit for completing this program.

This program is approved for 6.0 contact hours of continuing education (which includes 4.75 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1209349

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.


## What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	0	0.00	0.00
DO	0	0.00	0.00
NP	25	60.98	60.98
PA	16	39.02	39.02
RN	0	0.00	0.00
Other	0	0.00	0.00
Total Valid	41	100.00	100.00




## What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	21	51.22	51.22
Endocrinology	1	2.44	2.44
Rheumatology	0	0.00	0.00
Pulmonology	0	0.00	0.00
Cardiology	1	2.44	2.44
Gastroenterology	2	4.88	4.88
OB/GYN	2	4.88	4.88
Other	14	34.15	34.15
Total Valid	41	100.00	100.00




**Upon completion of this activity, I can now - Identify appropriate candidates for BMD testing incorporating the FRAX 10-year fracture risk into treatment decisions; initiate pharmacologic therapy for patients who meet NOF guideline recommendations for pharmacologic management; implement education for dietary and supplemental calcium and vitamin D and exercises to prevent osteoporosis and related fractures; and recognize and overcome barriers to adherence and effectiveness of osteoporosis therapy:**

Label	Frequency	Percent	Valid Percent
Yes	37	90.24	90.24
Somewhat	4	9.76	9.76
Not at all	0	0.00	0.00
Total Valid	41	100.00	100.00




**Upon completion of this activity, I can now - Explain the current pathophysiologic mechanisms associated with the development of psoriatic disease; discuss the impact of psoriatic disease including its effects on mood, cardiovascular risk, quality of life, and other co-morbid conditions; recognize the percent of body surface area that categorizes a patient for topical or systemic therapy; and implement appropriate treatment plans for patients who are candidates for topical and/or systemic therapy:**

Label	Frequency	Percent	Valid Percent
Yes	32	78.05	78.05
Somewhat	9	21.95	21.95
Not at all	0	0.00	0.00
Total Valid	41	100.00	100.00




**Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and nonpharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; and use currently available laboratory tests to maximize benefit while minimizing toxicity:**

Label	Frequency	Percent	Valid Percent
Yes	30	73.17	75.00
Somewhat	9	21.95	22.50
Not at all	1	2.44	2.50
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**Upon completion of this activity, I can now - Discuss the role of the incretin system in the pathophysiology of type 2 diabetes (T2DM); define the role of GLP-1 receptor agonist therapy in the treatment algorithm for T2DM; identify the features, benefits, and limitations of individual GLP-1 agonists; discuss the appropriate selection of GLP-1 receptor agonist therapy according to the glycemic disturbance most in need of correction:**

Label	Frequency	Percent	Valid Percent
Yes	34	82.93	87.18
Somewhat	5	12.20	12.82
Not at all	0	0.00	0.00
Total Valid	39	95.12	100.00
Total Missing	2	4.88	
Total	41	100.00	



**Upon completion of this activity, I can now - Use of the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify safe and effective use of new and emerging antithrombotic therapy for AF patients related to the risk stratification for stroke; and identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation:**


Label	Frequency	Percent	Valid Percent
Yes	30	73.17	88.24
Somewhat	4	9.76	11.76
Not at all	0	0.00	0.00
Total Valid	34	82.93	100.00
Total Missing	7	17.07	
Total	41	100.00	






### Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	29	70.73	70.73
Very Good	11	26.83	26.83
Good	1	2.44	2.44
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	41	100.00	100.00




### Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	24	58.54	58.54
Agree	16	39.02	39.02
Neutral	1	2.44	2.44
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	41	100.00	100.00




**Overall, this activity was effective in improving my knowledge in the content areas presented:**

Label	Frequency	Percent	Valid Percent
Strongly Agree	28	68.29	70.00
Agree	12	29.27	30.00
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**As a result of this activity, I have learned new strategies for patient care:**

Label	Frequency	Percent	Valid Percent
Strongly Agree	28	68.29	68.29
Agree	13	31.71	31.71
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	41	100.00	100.00




## How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	27	65.85	67.50
Somewhat likely	8	19.51	20.00
Unlikely	2	4.88	5.00
Not applicable	3	7.32	7.50
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




## When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	18	43.90	47.37
1-3 months	12	29.27	31.58
4-6 months	0	0.00	0.00
Not applicable	8	19.51	21.05
Total Valid	38	92.68	100.00
Total Missing	3	7.32	
Total	41	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Nelson Watts, MD (Osteo):**

Label	Frequency	Percent	Valid Percent
Excellent	36	87.80	90.00
Very Good	4	9.76	10.00
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brad P. Glick, DO (Psoriasis):**

Label	Frequency	Percent	Valid Percent
Excellent	30	73.17	75.00
Very Good	8	19.51	20.00
Good	2	4.88	5.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Mark Osterman, MD (IBD):**

Label	Frequency	Percent	Valid Percent
Excellent	21	51.22	55.26
Very Good	12	29.27	31.58
Good	5	12.20	13.16
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	38	92.68	100.00
Total Missing	3	7.32	
Total	41	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert S. Busch, MD (Diabetes):**

Label	Frequency	Percent	Valid Percent
Excellent	32	78.05	86.49
Very Good	5	12.20	13.51
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	37	90.24	100.00
Total Missing	4	9.76	
Total	41	100.00	




**In terms of delivery of the presentation, please rate the effectiveness of the speaker: Elizabeth A. Jackson, MD (AFib):**

Label	Frequency	Percent	Valid Percent
Excellent	25	60.98	78.13
Very Good	7	17.07	21.88
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	32	78.05	100.00
Total Missing	9	21.95	
Total	41	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Nelson Watts, MD (Osteo):**

Label	Frequency	Percent	Valid Percent
Excellent	36	87.80	90.00
Very Good	2	4.88	5.00
Good	2	4.88	5.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brad P. Glick, DO (Psoriasis):**

Label	Frequency	Percent	Valid Percent
Excellent	35	85.37	87.50
Very Good	3	7.32	7.50
Good	2	4.88	5.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Mark Osterman, MD (IBD):**

Label	Frequency	Percent	Valid Percent
Excellent	33	80.49	86.84
Very Good	3	7.32	7.89
Good	2	4.88	5.26
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	38	92.68	100.00
Total Missing	3	7.32	
Total	41	100.00	




**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert S. Busch, MD (Diabetes):**

Label	Frequency	Percent	Valid Percent
Excellent	30	73.17	83.33
Very Good	5	12.20	13.89
Good	1	2.44	2.78
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	36	87.80	100.00
Total Missing	5	12.20	
Total	41	100.00	



**To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Elizabeth A. Jackson, MD (AFib):**


Label	Frequency	Percent	Valid Percent
Excellent	29	70.73	90.63
Very Good	3	7.32	9.38
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	32	78.05	100.00
Total Missing	9	21.95	
Total	41	100.00	






**Which statement(s) best reflects your reasons for participating in this activity:**

Label	Frequency	Percent	Valid Percent
Topics covered	19	46.34	47.50
Location/ease of access	26	63.41	65.00
Faculty	3	7.32	7.50
Earn CME credits	34	82.93	85.00
Total Valid	40	97.56	100.00
Total Missing	1	2.44	
Total	41	100.00	



**Future CE activities concerning this subject matter are necessary:**

Label	Frequency	Percent	Valid Percent
Strongly agree	16	39.02	41.03
Agree	18	43.90	46.15
Neutral	4	9.76	10.26
Disagree	0	0.00	0.00
Strongly Disagree	1	2.44	2.56
Total Valid	39	95.12	100.00
Total Missing	2	4.88	
Total	41	100.00	



## What is your professional degree?

Comment

Social Worker

## What is your specialty?

Comment

Neurology

Student

Dermatology

Pediatrics

Psychiatry

Psychiatry

Internal Medicine

Family Practice

Psychiatry

Palliative Medicine

Psychiatry

## As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment

CHAD score for talking to patients about risk of Afib; examining for joints and other co-morbidity with Psoriasis; increase use of GLP-1 as a second step for Diabetes

Treatment options for osteoporosis; additive therapy for psoriasis; treatment for IBS

I will use CHADS2 to evaluate A-fib patients. I will have better algorithms for treating diabetes patients. I have a better understanding of differentiating ulcerative Colitis from Crohn's disease

Use protocols/guidelines for treatment

Better dermatology dx/tx-initiating therapy I usually didn't use in the past

Implement more Methotrexate/Sonotane for the appropriate patient population. I personally will start a multivitamin and consider Ca24 supplementation to prevent osteoporosis! I will review old diabetic meds outside this lecture to increase my knowledge. Will implement new strategies discussed in the psoriasis lecture, otherwise, the remaining topics are unrelated for the most part to my practice of dermatology

Resources for screening/identification of patient that I should consider osteoporosis, IBS, psoriasis

Treatment options for osteoporosis; better understanding of combination therapy and biological drug initiation with psoriasis; increase understanding of initiating GLP-1 therapy in my practice

Not all osteoporosis agents treat hip fracture; may use if put on

Implementing risk stratification in screening and deciding treatment options

More frequent screening for osteoporosis

I have learned enough regarding the orthophysiology, signs and symptoms, diagnostic measures, and treatment choices to help me with decisions and Rx of covered topics

Comment
Identifying various pt groups. Learning various disorders that are likely to exacerbate underlying psychiatric illness; improving current tx regimens within my patient population
Evaluate BMD yearly for MC patients on tx; was testing every 2 years; initiate GLP-1 treatment sooner; educate pe: blood thinners and new drugs available
Look at patients in a broader fashion-reviewing more signs, symptoms; using guidelines mentioned today
I will make sure to add other options
Become more familiar and confident to start patients on medication; close follow ups
Appropriate medication choice for prevention of fx in tx osteoporosis
Use CHADS score more often; possible use of Pradaxa
GLP-1 therapy
Alternatives to insulin in managing DM
Identifying people who need treatment for osteoporosis; starting initial treatment for psoriasis; checking Hepatitis B prior to initiating Crohn's/UC therapy
BMD guidelines; first line drugs for psoriasis; DM mgmt
I have better understanding of differences between Byetta and Victoza. Will use Byduneon more; know some options for psoriasis before refer to dermatology
When to get best AIC reduction and weight loss with; risks stratification of AF and new treatment guidelines
Assessing for DXA candidates; assessing joints in clients with psoriasis
Becoming aware of most current guidelines; using evidence based medicine; becoming familiar with new, innovative Rx
CHADS, GLP vs DPPX, FRAX
Watch for arthritis and psoriasis; differentiation of IBD, IBS, Crohn's, UC

## What topics would you like to see offered as CE activities in the future?

Comment
End stage for renal disease
Parkinson's, seizures, migraines, kidney disease
Pediatric, neurology, dermatology
Any
Further DM mgmt, risk stratification/screening strategies for chronic diseases, LCD-10 changes to coding
All 5 were excellent! Particularly a need for the IBD and diabetes lectures
Pediatrics-ortho, urology, behavioral
ESRD, asthma
Women's health; pain management
HIV
Hyperlipidemia and IBS
Diabetes, pain management, CHF, COPD, or a day conference based on a specialty of medicine covering the top 5 diseases within specialty
The conference was great and well balanced. For my field, I would also include hypertension and hyperlipidemia
Quick update on depression/anxiety as most patients often present to PCP prior to going to see psychiatrist
Thyroid disease
Renal failure, HTN-control, lipid control, CHF
Psychiatry-anxiety disorder ADHD in adults; diet
Thyroid disease, hypertension
Orthopedics and psych
Testosterone deficiency, anxiety/depression, DM
Depression, other dermatology topics, geriatric medicine topics, pain control, dementia
Excellent-Deborah was great! ENT topics
More dermatology
Coding especially Medicare physicals
Fatty Liver disease
HIV
Women's health topics; sexually transmitted infections; depression/anxiety update; domestic violence; birth control options
Women's health issues; some pediatric issues
Women's health topics
Psychiatric d/o
Pain management, depression, Alzheimer's
ENT related topics
Any psych topics eg addiction, mood disorders

## Additional comments:

Comment
Very good seminar. Good lunch. Thank you
This was excellent! Hope to return next year
Very enjoyable and useful
Thank you for providing this free CME
I'm highly impressed that this course is no charge, has breakfast and lunch provided, nutritional beverages, and excellent speakers!! Who funds this course?!! It's such an excellent academic opportunity
I work in a specialty-I have to recertify in General Medicine as a PA. These are good ways to learn about topics I don't see for test prep
Good lunch perfect
List instructions on how to get certificate online in booklet handout. Handout was great to follow along with and take notes. Great food and drink options
Great conference. I look forward to receiving information on future meetings
I appreciate to simplicity teaching and better understanding of the subjects discussed
Thank you
Great conference, thanks! Room cold-I did wear/bring sweater
It would have been helpful to have brand names available in the slides or mentioned during discussion
Thank you
The conference was great. Content was relevant and speakers exceptional. I prefer not to have the group discussions although I can see how they benefit some.
Thank you
Great speakers
Great conference! Thank you so much for offering this wonderful opportunity for education and networking! I will definitely be returning
Very impressed with the quality of this conference. I'll be back
Thank you
Thank you
Thank you so much for the program notes/pamphlet

## Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	3.39	4.05	1.10	1.22	1.28	1.13	1.12
Variance	0.24	11.10	0.09	0.18	0.26	0.11	0.11
Standard Deviation	0.49	3.33	0.30	0.42	0.51	0.34	0.33
Standard Error	0.08	0.52	0.05	0.07	0.08	0.05	0.06
Minimum	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	4.00	8.00	2.00	2.00	3.00	2.00	2.00
Median	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	7.00	1.00	1.00	2.00	1.00	1.00

	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care	Make Changes	Implement New Strategies	Nelson Watts MD {Osteo}
Mean	1.32	1.44	1.30	1.32	1.53	1.95	4.90
Variance	0.27	0.30	0.22	0.22	0.82	1.35	0.09
Standard Deviation	0.52	0.55	0.46	0.47	0.91	1.16	0.30
Standard Error	0.08	0.09	0.07	0.07	0.14	0.19	0.05
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	4.00
Maximum	3.00	3.00	2.00	2.00	4.00	4.00	5.00
Median	1.00	1.00	1.00	1.00	1.00	2.00	5.00
Range	2.00	2.00	1.00	1.00	3.00	3.00	1.00

	Brad P Glick DO {Psoriasis}	Mark Osterman MD {IBD}	Robert S Busch MD {Diabetes}	Elizabeth A Jackson MD {AFib}	Nelson Watts MD {Osteo} Bias	Brad P Glick DO {Psoriasis} Bias	Mark Osterman MD {IBD} Bias
Mean	4.70	4.42	4.86	4.78	4.85	4.83	4.82
Variance	0.32	0.52	0.12	0.18	0.23	0.25	0.26
Standard Deviation	0.56	0.72	0.35	0.42	0.48	0.50	0.51
Standard Error	0.09	0.12	0.06	0.07	0.08	0.08	0.08
Minimum	3.00	3.00	4.00	4.00	3.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Range	2.00	2.00	1.00	1.00	2.00	2.00	2.00

	Robert S Busch MD {Diabetes} Bias	Elizabeth A Jackson MD {AFib} Bias	Reasons for Participating	Future CE Activities
Mean	4.81	4.91	-	1.77
Variance	0.22	0.09	-	0.71
Standard Deviation	0.47	0.30	-	0.84
Standard Error	0.08	0.05	-	0.13
Minimum	3.00	4.00	-	1.00
Maximum	5.00	5.00	-	5.00
Median	5.00	5.00	-	2.00
Range	2.00	1.00	-	4.00